Enwei Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Enwei Pharmaceutical's earnings have been declining at an average annual rate of -12%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 5.5% per year. Enwei Pharmaceutical's return on equity is 3.5%, and it has net margins of 4.6%.
Belangrijke informatie
-12.0%
Groei van de winst
-20.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 5.5% |
| Rendement op eigen vermogen | 3.5% |
| Nettomarge | 4.6% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Enwei Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 776 | 35 | 339 | 8 |
| 30 Jun 24 | 778 | 40 | 334 | 12 |
| 31 Mar 24 | 778 | 68 | 306 | 16 |
| 31 Dec 23 | 785 | 86 | 293 | 17 |
| 30 Sep 23 | 778 | 91 | 284 | 18 |
| 30 Jun 23 | 752 | 93 | 268 | 14 |
| 31 Mar 23 | 735 | 75 | 276 | 9 |
| 01 Jan 23 | 692 | 68 | 260 | 8 |
| 30 Sep 22 | 676 | 86 | 253 | 6 |
| 01 Jan 22 | 680 | 102 | 265 | 4 |
| 30 Sep 21 | 675 | 103 | 240 | 4 |
| 31 Dec 20 | 634 | 99 | 243 | 5 |
| 31 Dec 19 | 621 | 83 | 294 | 4 |
| 31 Dec 18 | 593 | 86 | 291 | 4 |
| 31 Dec 17 | 559 | 64 | 272 | 4 |
Kwaliteitswinsten: 301331 has a large one-off gain of CN¥9.4M impacting its last 12 months of financial results to 30th September, 2024.
Groeiende winstmarge: 301331's current net profit margins (4.6%) are lower than last year (11.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 301331's earnings have declined by 12% per year over the past 5 years.
Versnelling van de groei: 301331's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 301331 had negative earnings growth (-61.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 301331's Return on Equity (3.5%) is considered low.